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Abstract
Background: It is estimated that around 70% of Type 2 Diabetes Mellitus patients (T2DM) have Non-Alcoholic Fatty
Liver Disease (NAFLD). Awareness and education are amongst the major shortcomings of the public health
response to the increasing threat of NAFLD. Characterizing the specific NAFLD-related information needs of
particular high-risk metabolic communities, for instance, T2DM patients, might aid in the development of evidence-
based health promotion strategies, ultimately promoting NAFLD-awareness, treatment adherence and therapeutic
success rates.
Methods: Semi-structured interviews with T2DM patients were conducted to gain insight into their awareness of
NAFLD, including its relationship with insulin resistance and T2DM.
Results: Awareness of NAFLD as a disease entity, as well as its progression to end-stage liver disease or its
relationship with other metabolic conditions, including insulin resistance and T2DM was low. Surveillance
behaviours were also suboptimal and perceptions on the self-management knowledge and praxis regarding
lifestyle intervention components of T2DM treatment seemed detached from those of NAFLD.
Conclusions: Our findings could inform the integration of NAFLD-related content in T2DM health promotion
strategies. Rising awareness on NAFLD progression and its relationship with T2DM using culturally and community-
relevant constructs might facilitate the development of primary and secondary prevention programmes to promote
the adherence to lifestyle interventions by influencing NAFLD threat perceptions.
Keywords: NAFLD, Awareness, Knowledge, Education, Self-management, T2DM, Qualitative research, Risk
communication
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Background
Non-Alcoholic Fatty Liver Disease (NAFLD), affecting
25% of the global population, is currently the most com-
mon chronic liver disease worldwide and constitutes an
increasing threat to public health both at economic and
clinical levels [1–3]. The most benign form of NAFLD is
characterized by the presence of micro- or macro-
vesicular steatosis in ≥5% of hepatocytes in the absence
of other recognized aetiological factors [4]. However, the
NAFLD continuum ranges from simple hepatic steatosis
to the more severe form of Non-Alcoholic Steatohepati-
tis (NASH), a state of inflammation that in turn can pro-
gress to end-stage liver disease, including cirrhosis and
Hepatocellular Carcinoma (HCC) [4–6].
Rarely circumscribed to the liver, the pathogenic
burden of NAFLD is rather systemic. The excessive
energy intake associated with the consumption of
hypercaloric diets and the low energy requirements of
sedentary lifestyles cause a homeostatic imbalance and
the net retention of energy in the form of fat. This
chronic metabolic imbalance underlies the develop-
ment of obesity, insulin resistance (IR), Metabolic
Syndrome (MetS), Type 2 Diabetes Mellitus (T2DM),
and the ectopic accumulation of fat within the hepatic
parenchyma [7–9]. Besides its shared aetiology, NAFL
D presents a strong bidirectional relationship with
MetS features and T2DM, exacerbating its severity
and progression rate [10, 11].
Although Cardiovascular Diseases (CVDs) are the first
cause of death in NAFLD patients, NASH significantly
contributes to the mortality burden of cirrhosis and
HCC, which combined account for 3.5% of deaths
worldwide [2, 12, 13]. Population aging and the rising
prevalence of T2DM, a risk factor for cirrhosis progres-
sion from NASH, predict an upcoming increase in liver-
related mortality due to NAFLD [3] and envision NAFL
D to become the leading cause of liver transplantation in
Europe in the near future [14].
Despite the threat that NAFLD poses to human health,
the public health response to NAFLD is straggling at
multiple levels [15, 16]. NAFLD awareness amongst
healthcare providers is low and adherence to NAFLD
clinical guidelines regarding diagnosis, monitoring, and
management is poor [17–20]. Similarly, NAFLD aware-
ness amongst metabolic patients and the general popula-
tion is scant [21–24] and therapeutic adherence amongst
NAFLD patients is poor [25–27].
Whilst only 2% of the 5000 participants of a survey in
New York City had heard of NAFLD, 17% of the 521 re-
spondents to a telephone survey in Hong Kong had pre-
viously heard of NAFLD [21, 22]. Similarly, only 18% of
302 respondents in a study in Colorado had previously
encountered the terms “Non-Alcoholic Fatty Liver Dis-
ease”, “NASH” or “fat in the liver” [23]. These studies
suggest that NAFLD awareness is gained by interaction
with healthcare providers [21, 23].
Lifestyle interventions addressing dietary regimes and
physical activity patterns are the standard of care for
NAFLD whilst constituting a crucial component of
therapeutic strategies targeting other metabolic diseases
[28, 29]. However, structured lifestyle programs to treat
NAFLD are only provided in 7 European countries [30]
and often report low success rates in promoting the
weight loss necessary for an improvement in NASH
histological features including fibrosis regression [29,
31–33]. Moreover, scarce motivation to adopt healthier
lifestyles regarding nutrition and physical activity has
been reported by a study exploring the readiness of
NAFLD patients for behavioural changes [34]. Posited
by models of health promotion, disease prevention and
therapeutic adherence, the adoption of health behaviours
is dependent upon disease awareness, disease-related
practical skills, individual beliefs regarding disease and
treatment, motivation and perceptions of self-efficacy
[35–38]. Although several NAFLD-awareness campaigns
are ongoing [30, 39, 40] and some lifestyle intervention
studies currently include educational or psycho-
behavioural components [32, 33, 41, 42], these seem
largely designed from a top-down perspective. Yet,
current models of health communication advocate tai-
loring the initiatives to the individual or community’s
existing knowledge and capacities, ultimately providing
the context-specific health knowledge and fostering the
self-efficacy required to exert better control over their
health [38, 43, 44].
Considering that the prevalence of NAFLD amongst
T2DM patients is estimated to be as high as 70%, raising
NAFLD awareness within this community seems of par-
ticular importance [45]. In this study, we intended to
gain some insight into the NAFLD-related experiential
and factual knowledge possessed by a group of T2DM
patients and how that information may be used to make
them more NAFLD-aware. Adding to the scarce litera-
ture in NAFLD awareness and complementing its focus
on the quantification of pre-established theoretical con-
structs, the exploratory nature of qualitative research
should contribute towards uncovering unforeseen ideas,
understandings, opinions and motivations with potential
to inform NAFLD public health interventions [46].
Methods
Through a descriptive qualitative approach and under an
interpretivist paradigm, this cross-sectional study sought
to investigate T2DM patients’ awareness about NAFLD
within the context of their T2DM illness and therapeutic
experience [47]. For this purpose, semi-structured inter-
views were conducted at the Portuguese Diabetes Asso-
ciation (APDP). The development of the interview guide
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and the conduction of the interviews were performed by
researchers with a biomedical background that facilitated
content selection and the recognition and understanding
of medical concepts shared by participants. Intending to
challenge pre-established assumptions inherent within
this biomedical perspective and trying to complement
potential design and interpretation biases, the view of re-
searchers with a background in psychology, sociology,
patient communication and qualitative research were
sought during the design and data analysis phases of the
study.
Research setting
The study was conducted at the Portuguese Diabetes As-
sociation (APDP), located in Lisbon (Portugal). Founded
in 1926, APDP is the oldest diabetes association in the
world. Initially conceived as a philanthropic organization
seeking to provide free insulin to those who could not
afford it, nowadays it is a modern health institution
catering comprehensive diabetic care for over 30.000
members [48]. The APDP outpatient clinic is composed
of a multidisciplinary team that provides integrated clin-
ical care, serving as an ambulatory care facility for dia-
betic patients and as a referral site for complications
management. Its approach is deeply invested in defend-
ing the rights of people with diabetes and their inclusion
in society. Alongside medical services, APDP educational
interventions strive towards patient empowerment by
fostering self-management behaviours, discussing T2DM
biomedical knowledge, glycaemic control, insulin ther-
apy and foot care, as well as providing nutrition work-
shops, cooking classes, exercise training and workout
sessions [49, 50]. There is no hepatology service at
APDP and none of the education sessions are focused
on NAFLD, thus providing the ideal setting of awareness
for some aspects crucial for NAFLD without focusing on
the disease itself.
Development of the semi-structured interviews guide
The development of the semi-structured interview guide
followed a sequential curation process. The content of
the questions was decided according to the research
aims and taking into account the available literature on
NAFLD awareness consisting of quantitative studies
employing the use of questionnaires and surveys to ac-
cess large cohorts of participants [21–23]. The initial
compendium for the interview included 18 questions re-
garding awareness of NAFLD as a diagnosis entity as
well as epidemiology, aetiology, progression, prognosis,
prevention and treatment of the disease, NAFLD risk
perception in a T2DM context and general interest in
NAFLD information.
Researchers MMR and SA, with a background in psych-
ology and sociology, respectively, provided feedback on
the interview guide draft based on their previous experi-
ence in qualitative research. Integrating their input, the
topics of the interview were reformulated to better allow
patients to share their experiences and reasoning and to
facilitate a continuous flow of conversation. To that end
and taking into account the expected low degree of NAFL
D awareness, the first questions were dedicated to asking
about participants’ knowledge about T2DM, with which
they would be more familiar, rather than NAFLD. We be-
lieve this would set the context for exploring the relation-
ship of participants with NAFLD-related topics. The
interview guide included other topics that were then fur-
ther elaborated by the participants, such as liver physi-
ology, NAFLD pathophysiology and knowledge on dietary
and exercise behaviours. This approach was substantially
different from previous quantitative studies, which were
designed from a health policy and management perspec-
tive, and thus probed awareness of NAFLD prevalence,
diagnostic methods and clinical symptomatology. The
content and structure of the interview guide were dis-
cussed between the research team, composed by psycholo-
gists, sociologists, biomedical researchers and a nurse
practitioner to assure that it assessed relevant content re-
garding the study goal and that it was formulated to allow
participants to express their views on the topics.
This version of the semi-structured interview consisted
of 15 topics with probes enquiring about: a) T2DM dis-
ease knowledge and illness perceptions, b) knowledge on
insulin resistance and the interplay between NAFLD and
T2DM, d) liver function, fatty liver awareness, NAFLD
disease knowledge on pathophysiology and progression
of the disease, e) cirrhosis awareness and relationship
with NAFLD, f) role of diet and exercise on T2DM and
NAFLD therapeutic approaches and e) interest in receiv-
ing NAFLD education.
Study population and data collection
From October to December 2018, 35 people attending
consultation at the Portuguese Diabetes Association
(APDP) in Lisbon were invited to participate in this
study. A purposeful random sampling strategy on the
basis of a diagnosis of either T2DM or pre-diabetes was
used to select participants [51]. Recruitment was con-
ducted in person at one of the waiting rooms of APDP
headquarters. The waiting room manager provided an
attendance list and appointed those patients with a lon-
ger waiting time for consultation. Those patients were
sequentially and consecutively approached by researcher
AMA and briefly introduced to the study. Participation
was voluntary and involved face-to-face semi-structured
interviews conducted in a private room at APDP by re-
searcher MAP with AMA as an observer. MAP and
AMA did not have contact with any of the participants
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prior to undertaking this study nor had any role in the
clinical management of the interviewees.
The order and phrasing of the questions were
adapted to each individual case, whilst probing and
clarifying questions were used to facilitate information
disclosure. The interview guide evolved through the
process of data acquisition and analysis, enabling a
better exploration of preestablished and emergent
themes. The item of NAFLD surveillance behaviours
was added after the first round of interviews and the
item of interest in receiving NAFLD education was
deemed redundant and dropped (the initial interview
guide is available at Supplementary file 1).
The duration of the interviews was of approximately
30 min, which allowed for exploration of the topics of
interest, including exemplifications by the patient and
follow-up questions by the researchers. At the end of the
interview, participants filled an anonymized demograph-
ics questionnaire that collected information regarding
patient code, age, gender, level of education, occupation
and time since T2DM diagnosis. The illustrative quota-
tions in the results section are identified following (pa-
tient code, gender, age-range, education); the latter
categorized in NO, no formal education; 1 °C, 1st cycle
of primary school; 2 °C, 2nd cycle of primary school;
3 °C, 3rd cycle of primary education; SEC, secondary
education; HI, higher education. The medical file of
participants was not accessible. Except for T2DM sta-
tus, all clinical information discussed here was ob-
tained from patient recollections. All interviews were
conducted in Portuguese and audiotaped with a voice
recorder. Data collection was continued until thematic
saturation was reached, a point in which the low ex-
pected incidence of new ideas in the data did not
warrant further exploration [52]. Qualitative research
expands the possibilities of addressing unpredicted
topics and deeply understanding people’s choices and
behaviours. At the same time, we acknowledge that
the data collected is influenced by the research aims,
the formulation style of the questions and the listen-
ing skills of the researcher conducting the interviews.
The first round of interviews was immediately tran-
scribed, evaluated and discussed by the multidisciplin-
ary team in order to identify personal bias, correct
the interviewer’s posture and minimize any form of
unintended coercion on the interviews.
Ethical considerations
This study was approved by the Ethics Committee for
Health of APDP and written informed consent was ob-
tained from all participants in the study before initiating
the interviews. No compensation was provided to
participants.
Data analysis
All voice recordings were transcribed verbatim by a
professional. The transcripts were read a first time for
familiarization with the data and to check for tran-
scription accuracy. A content analysis methodological
approach guided the analytical process directed at
unveiling the degree of NAFLD-awareness amongst
T2DM patients, including their perceptions and fac-
tual biomedical knowledge on the disease [53]. The
interviews were analysed using MAXQDA Standard
2018 (VERBI Software, 2017) [54]. The transcripts
were imported to MAXQDA as soon as they were
available and the process of data analysis was initiated
concurrently with the last stages of data collection.
Individual interviews were used as units of analysis,
which was performed by the first author. The early
transcripts served as a sample to systematically search
and identify concepts of interest embedded in the
participants’ responses to the open-ended questions of
the interview process. Each of these concepts of inter-
est was assigned a code. A preliminary coding scheme
was developed based on the emerging patterns and
repetitions found across transcripts. By fitting and
grouping the coded concepts into pre-established
themes, a final coding scheme was defined. All tran-
scripts were sequentially analysed to fit the data into
the following key themes: a) NAFLD-awareness, in-
cluding aetiology and treatment, b) Progression to
end-stage liver disease, c) Surveillance behaviours, d)
T2DM Self-Management Knowledge and e) NAFLD
risk perception. Using the strategy of persistent obser-
vation to ensure the credibility of the results, several
consecutive analytical rounds were performed in each
of the transcripts [55–57].
Researcher triangulation and audit trials were used to
ensure rigor and analytic trustworthiness. The interview
guide drafting process, the design of the study and the
procedures used for recruitment, sampling, data collection
and analysis were documented and stored. Alongside the
first author as the main coder, the author MMR per-
formed an independent analysis in 50% of all transcripts
developing a parallel code book on the concepts of NAFL
D-awareness, aetiology and treatment, as well as surveil-
lance behaviours, which were provided to her as preestab-
lished themes into which to fit the observed data. As a
clinical psychologist, the expertise of MMR complemen-
ted that of the first author, trained in biomedical sciences.
Used to calculate interrater reliability, the Average Kappa
coefficient was of 8.89, suggesting strong agreement [58].
Later, the two authors (MAP and MMR) compared codes,
discussed convergences and discrepancies and reached full
consensus. The findings are reported below in anon-
ymized quotes that were translated into English from the
verbatim interview transcripts.
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Results
Response rate and demographics
A total of 35 patients were approached to participate in
this study whilst awaiting consultation. One patient
refused to participate and one was not eligible for par-
ticipation due to the lack of a T2DM diagnosis. The
remaining 33 patients were interviewed between
October 4th and December 7th, 2018. Three participants
were excluded from the study after voluntarily interrupt-
ing the interview process, all but one out of concern of
missing the medical appointment.
In the end, 30 of the T2DM patients approached
were included in the study (attrition rate 14%). The
median age of the participants was 65 years, 53% were
female and 66% reported at least another case of
T2DM in the family (Table 1). Of the 30 participants,
10 had been diagnosed with NAFLD in the past, in-
cluding metabolic and drug-induced forms of NALFD.
Considering that the highest incidence of T2DM is
between the ages of 45 and 65 and that its prevalence
increases with age, the epidemiological profile of this
elderly cohort is similar to that of the global T2DM
patient population and that of patients receiving care
at APDP [59].
NAFLD-awareness
NAFLD disease identity and causes
The term fatty liver was recognized by a total of 15 par-
ticipants (Table 2). Of those, the majority were aware of
the disease term because they had been diagnosed with
NAFLD in the past or were suffering from NAFLD at
the time. The rest had close relatives affected by the dis-
ease or gained awareness as a result of health
information-seeking behaviours.
“At the level of the liver, it seems that it is not that
bad, even though there is a bit of fat in the liver.”
(#127.1, ♂, 61-70 years old, HI)
Infection by hepatitis virus, alcohol and non-alcoholic
fatty liver disease, the latter encompassing both drug-
induced NAFLD and metabolic NAFLD, were
mentioned as the aetiological factors responsible for the
development of fatty liver. Hypertriglyceridemia, hyper-
cholesterolemia or the consumption of high-fat diets
were the most commonly mentioned causes for meta-
bolic NAFLD.
“I know that the fatty liver is from someone that has
an excess of fat, or that has, eventually, higher levels
of cholesterol. [...] But the, the fatty liver, in addition
to being associated to, to an increase in volume, for
some reason, I know it has to do with, with the liver
not, not working so well in terms of the capacity of,
of processing fats.” (#116, ♂, 61-70 years old, HI)
“The liver, look, when I had very high levels of tri-
glycerides, the triglycerides attack the liver, I think.
In the beginning they said that I drank a lot. I drink.
Now I drink even less, but I was never an alcoholic
… [...] Well, I have the liver, a bit fatty. Why, I don’t
know, since the diet that I do is a moderate diet, I
don’t eat fats, the food, when it goes to the pan, it
already has no fats, and then, even in the plate, I
even remove all the fats. I take [medication], that is
to reduce my triglycerides. To clean up, clean up
the fat from the blood, but I don’t eat fats. Who
knows what this is.” (#106, ♂, >70 years old, 3°C)
Liver function and consequences of NAFLD
Knowledge about the liver and its physiological func-
tions was scarce. About a third of the respondents
perceived the liver as a filter for blood purification and 2
mentioned the production of bile but none recognized
the role of the hepatic tissue in metabolism and energy
homeostasis. There was a generalized lack of knowledge
on the consequences of steatosis. A minority of patients
mentioned hepatomegaly and the progressive loss of
Table 1 Demographic profile
N (%)
Gender
Female 16 (53)
Male 14 (47)
Age (years), median (SD) (range) 65 (8.99) (50–87)
50–60 years 9 (30)
61–70 years 11 (37)
> 70 years 10 (33)
Education Attainment
< 4 years (No Formal Education; NO) 1 (3)
4 years (1st Cycle Primary Education; 1 °C) 10 (33)
6 years (2nd Cycle Primary Education; 2 °C) 4 (13)
9 years (3rd Cycle Primary Education; 3 °C) 2 (7)
12 years (Secondary Education; SEC) 4 (13)
> 12 years (Higher Education; HI) 9 (30)
Employment status
Employed 10 (33)
Unemployed 1 (3)
Retired 19 (63)
Type 2 Diabetes Mellitus (years), median (SD) (range)
Time since diagnosis 17 (13.46) (0–48)
The illustrative quotations are identified following (patient code, gender, age,
education); the latter categorized in NO, no formal education; 1 °C, 1st cycle of
primary school; 2 °C, 2nd cycle of primary school; 3 °C, 3rd cycle of primary
education; SEC, secondary education; HI, higher education
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Table 2 Prevalence of NAFLD awareness and NAFLD-related beliefs
N % NAFLD-Aware % Total
NAFLD awareness
NAFLD as disease entity
NAFLD awareness 15 100 50
History of NAFLD 10 66.67 33.33
NAFLD causes
High-Fat diets, hypercholesterolemia or hypertriglyceridemia 9 60.00 30.00
Alcohol 7 46.67 23.33
Hepatitis virus 2 13.33 6.67
Pharmacological drugs 2 13.33 6.67
Liver function
Filter for blood purification” 9 30.00
Secretion of bile for digestion 2 6.67
Metabolism / Energy homeostasis 0 0.00
NAFLD treatment
Dietary regimes 6 40.00 20.00
Physical activity or exercise regimes 1 6.67 3.33
Progression to end-stage liver disease
Cirrhosis as disease entity
Cirrhosis awareness 27 90.00
Liver as affected organ 24 80.00
Life-threatening status 12 40.00
Awareness from vicarious experience 14 46.67
Cirrhosis causes
Alcohol 24 80.00
Non-identified factor 9 30.00
Fatty Liver 3 10.00
T2DM 1 3.33
Hepatitis Virus 1 3.33
Pharmacological drugs 3 10.00
NAFLD risk perception
Insulin resistance awareness 0 0.00
Relationship between liver or NAFLD and T2DM
NAFLD and T2DM - shared underlying cause 2 6.67
NAFLD and T2DM - no etiological relationship 2 6.67
NAFLD as a risk factr for T2DM 1 3.33
T2DM as a risk factor for liver damage 7 23.33
NAFLD surveillance behaviors
NAFLD-aware with prior diagnosis 5 16.67
NAFLD-aware with no prior diagnosis 1 3.33
T2DM self-management knowledge
Dietary knowledge
Hyperglycemic effect of food intake 24 80.00
Avoidance or reduction of both simple and complex carbohydrates 15 50.00
Glycemic impact of simple and complex carbohydrates 7 23.33
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hepatic function after enquiring what happens in the
liver when it becomes fatty.
“[The liver] is the one that produces … so, it purifies
the blood, right? And then it even produces a sub-
stance that is also secreted into the food … and that
helps to make the digestion, right?” (#132.1, ♀, 61-
70 years old, SEC)
“Yes, about the liver, sometimes, the, in the morn-
ing, after a period of fasting a bit long, I have the
diabetes high and they tell me it can be, it might
have been low, but the liver, to compensate, started
to, to strain for insulin, or to make the insulin go
up. It’s not the insulin, sorry, yes … To rise the gly-
cemia.” (#124, ♀, 61-70 years old, HI)
NAFLD treatment
Whilst dietary behaviours were often recognized as a
component of NAFLD management actions, these
participants seemed not to grant this lifestyle modifi-
cation a therapeutic status. Exercise as part of the
management strategy for NAFLD was mentioned by
one participant. There was no reference to the benefi-
cial effects of T2DM pharmacological agents on
NAFLD, although some patients referred to anti-
hypertriglyceridemic agents or antiviral medication as
part of their fatty liver treatment.
“None. It is to eat, the more salads the better, and
more stews and broils. It was what they ordered me
to do. Now, medication I am not taking any.” (#105,
♀, 50-60 years old, 1°C)
“Ah, it is that same old conversation as always. It
is the diet, it is the practice of exercise, it is tak-
ing care of the diet, it is not smoking, it is not
drinking. It is all those things that are applicable
to any little thing.” (#122.1, ♀, 50-60 years old,
HI)
Progression to end-stage liver disease
The concept of cirrhosis as a disease entity was recog-
nized by the vast majority of participants. In most cases,
patients identified the liver as the organ being affected
and associated the disease with the excessive consump-
tion of alcohol. Surprisingly, it was also recognized by
more than half of the participants, that factors other
than alcohol, in most cases reported as unknown, could
also cause cirrhosis.
“Yes, the cirrhosis is in the liver, but I don’t drink.
They say that it is from drinking, it gives cirrhosis. [
… ] The liver melts all down. The liver doesn’t … ,
starts to bloat a lot. There is a guy next door, that,
that one drinks Whiskey and, and such, he has been
hospitalized a few times, he is about to die, but then
he comes back. He bloats. He is slim, but he has a
giant belly. It is the liver, the liver makes it bloat, it
starts to be, and laying down, he removes, he had to
remove liquids … because he is … , he is sick. It is be-
cause of the alcohol.” (#119, ♀, 61-70 years old, 1°C)
“And there are people that has cirrhosis and that
never drank. Did you know? I think you know. And
I also cannot, cannot explain why, because, usually,
between people that drink, that drink a lot have cir-
rhosis. But there are people that never drank and
already had cirrhosis and died of cirrhosis.” (#101,
♂, 50-60 years old, HI)
Showing a clear lack of awareness on the progression of
NAFLD towards late-stage liver disease, only 3 patients
reported a clear association between fatty liver and cir-
rhosis. Other identified causes of cirrhosis included viral
infection, medical drugs and T2DM. Awareness of
Table 2 Prevalence of NAFLD awareness and NAFLD-related beliefs (Continued)
N % NAFLD-Aware % Total
Avoidance or reduction of simple sugars 9 30.00
Glycemic impact of simple sugars 7 23.33
Avoidance or reduction of complex sugars 4 13.33
Glycemic impact of complex sugars 0 0.00
Avoidance of fat 20 66.67
Glycemic impact of fat consumption 6 20.00
Portion size reduction (caloric restriction) 18 60.00
Exercise knowledge
Hypoglycemic effect of exercise practice 18 60.00
Abbreviations: NAFLD Non-Alcoholic Fatty Liver Disease, T2DM Type 2 Diabetes Mellitus
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cirrhosis being a life-threatening condition was preva-
lent, as mentioned by a total of 12 respondents.
“I think that [cirrhosis] is, is what you call a very ad-
vanced state of fatty liver, isn’t it? And the liver does
no longer work, or will work very badly when it
reaches that state, isn’t it?” (#109.1, ♂, 50-60 years
old, HI)
“Cirrhosis yes, that is already a disease that, a liver
disease, isn’t it? And in the past, associated with al-
coholic beverages, but this doesn’t need to be the
case. Associated with alcoholic drinks, isn’t it? It
can be associated with diabetes. [ … ] Yes, but this,
because the blood that transports the fats, the
sugars and who knows what more, ends up tiring
the liver, no? With so much, with so much stuff,
maybe.” (#132.2, ♀, 61-70 years old, SEC)
The interview guidelines did not include any explicit en-
quiries regarding Hepatocellular Carcinoma (HCC) and
no unprompted mentions by the participants were ob-
served in this study. Conceptual representations on the
effects of cirrhosis on the morphology of the liver were
diverse, referring to its dilation or swelling, degradation,
melting down, burning out, destruction, or the state in
which the liver stops working or starts dying. This
knowledge seems to be mostly acquired through the ill-
ness experience of members of their social networks.
T2DM self-management knowledge
Knowledge of the multifactorial nature of T2DM treat-
ment was widespread. Regarding diet composition,
avoidance of either simple or complex sugars was ubi-
quitously referred. Whilst 9 participants reported the
need to avoid simple sugars, 4 indicated the need to re-
duce consumption of complex carbohydrates and 15 the
need to cut on both. Portion size reduction as a strategy
for caloric restriction was frequently mentioned. Avoid-
ance of fats in the diet was reported by two-thirds of the
participants. A total of 24 patients were aware of the
hyperglycaemic impact of food consumption. Of these,
14 focused on the role of carbohydrates in the diet, 7 pa-
tients reporting the hyperglycaemic influence of both
starches and simple sugars and the rest only referring to
the latter. Seeming to stem from experience rather than
medical instruction, the hyperglycaemic effect of lipid
intake was mentioned by 6 participants.
“Yes, salads, we can eat everything, but in very little
quantities. For example, boiled potatoes, these need
to be two small potatoes, of the size of an egg.
Then, I can eat all the vegetables that I want, greens,
broccoli, cauliflower, as a sider to that food to fill
up more the stomach, that’s it. Because that does
not make “the diabetes” go up. And if we were to
eat a lot of farinaceous foods, “the diabetes” goes up
later, isn’t it? I can’t eat a lot of bread, isn’t it? It also
makes them go up. If I eat a lot of fruit, they also go
up. We can only eat two pieces of fruit a day and
not so sweet. I know all of this, so be it that some-
times one flees. [ … ] More fish than meat because
it is healthier, isn’t it? In all ways. They don’t
have that much stuff for them to rise up. [And
fats?] Yes, nothing of fats, just white meats.
Rabbit, chicken, just white meats like this. Cow
meat and such, are not recommended for us to
eat, that’s it. Because it is fattier. That’s it. It’s
more, they recommend more grilled and boiled
meals." (#110, ♀, 50-60 years old, 1°C)
About half of the participants in this study report
having a clear structure for regular exercise practice,
mostly aerobic activity. The rest mentioned occasional
walks, work-related physical activity or home duties
as part of their activity. A total of 18 participants ac-
knowledged the effect of exercise practice on gly-
caemic control.
“People end up much more at ease. If I were to have
“the diabetes” a bit higher, I don’t mean that I was
to have, 200 and some like I have now, but if I were
to have 180 and I would want to lower it down, for
example, if I were to go do that exercise of the Free
Waters Aqueduct and come back, [ … ] and when I
go to measure, many times I have 140. I mean, I
guess it is from, from the exercise, that in the mean-
time, it made me lower it down.” (#112, ♀, 61-70
years old, 2°C)
NAFLD risk perception
Crucial to understanding the relationship between
T2DM and NAFLD, the term insulin resistance was
unknown to all study participants. Nonetheless, some
patients understood and elaborated on concepts re-
lated to IR. Two patients described the process of
gluconeogenesis as the responsible mechanism for
their fasting hyperglycaemia, although only one of
them attributed it to the liver (quote from #124
above). When enquiring about the connection be-
tween the liver or NAFLD and T2DM, responses
were diverse. Two participants considered that T2DM
and NAFLD share an underlying cause whilst two
others, explicitly reporting to be diagnosed with
NAFLD prior to the development of T2DM, did not
consider any aetiological relationship between the two
conditions.
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“Yes. The fatty liver happens through the excessive
accumulation of fat in the liver, isn’t it? Therefore,
and it makes it not work well, and alters some tests,
that are values of an analysis that, that are made,
from which you know if there is fatty liver or not, I
think, isn’t it? [ … ] Why is it that it accumulates
there, I don’t know...Probably because, I don’t know,
since that is a little filter of the blood, isn’t it? The
blood controls that whole thing, so the liver is there,
if the blood is not in good conditions, probably it is
all retained there, isn’t it? [ … ] I don’t associate
much the situation of the fatty liver with the insuffi-
ciency of the functioning of the pancreas. I don’t
know. But it will have more to do with other factors,
more diet-related.” (#109.2, ♂, 50-60 years old, HI)
“Yes. Ah, what is it that happens? Well, poor things,
our liver and our pancreas get tired and start to say
that they need a, a different kind of diet and a dif-
ferent type of life. If people don’t do it, it [interjec-
tion] it stops producing insulin. [ … ] The liver can
also be related with diabetes, yes sir, because the
liver, then, we don’t eliminate that what the liver
puts out there, it also helps all the rest, all the rest
helps the diabetes. This is all, all an endless cycle.
One thing leads to the other, the other leads to that
other, the other to the next, and the liver is in the
middle of all that.” (#122.2, ♀, 50-60 years old, HI)
One participant considered NAFLD to be a risk factor
for the development of T2DM.
“My son, for example, he doesn’t have diabetes, but
has fatty liver. [ … ] Listen, it’s like this. And that’s
it. But since he has fatty liver … , he could have dia-
betes, isn’t it? Maybe he has more … things to have
diabetes. [ … ] Already my niece, the daughter of my
sister [besides T2DM] also has fatty liver. But she is
all fatty, all of her.” (#111, ♀, >70 years old, 1°C)
Conversely, 7 patients conceived liver damage as a con-
sequence of T2DM. Of these, three were NAFLD aware
and four were NAFLD unaware. Interestingly, one of the
NAFLD unaware patients reported T2DM as a risk fac-
tor for the development of cirrhosis (quote #132.2
above).
“Yes, yes. So, the sugar is not absorbed or annulled,
let's call it this way, and it is hosted in other organs,
the liver, the kidneys, the sight, out there, damaging
them. [...] The fact that the liver has to work more or,
like, the sugar be, being more sugar than the liver can
process, or that has to analyse, causes that it becomes
not as healthy.” (#121.2, ♀, 50-60 years old, HI)
NAFLD surveillance behaviours
A total of 10 participants reported having had an ab-
dominal echography in the past as part of surveillance
behaviours to control the function of several organs, in-
cluding the liver. As mentioned above, NAFLD-aware-
ness seems to be associated with its diagnosis. Only one
of the NAFLD aware patients who did not have a NAFL
D diagnosis reported engaging in periodical echography
screenings. From those reporting a NAFLD diagnosis,
half did not perform any post-diagnosis follow-up exam
to verify the state of the liver and the possible progres-
sion of NAFLD along its continuum.
“The nephrologist told me: “It is not very worrying,
but I also noticed in the analysis that I requested
that, besides the, the, the small deviation in the
kidney, there is also something here in the liver, I
suggest you get that checked”. But in reality, I never
again...went to see that through, no.” (#127.2, ♂, 61-
70 years old, HI)
“Yes. It is the fatty liver. I also, at the time, I made
echography scans, indeed, I had fatty liver. After
that, I think I never again did any. That means, I
don’t know if it went down, if it still [laughs] has …
But yes, I already had the liver affected.” (#121.1, ♀,
50-60 years old, HI)
Discussion
To our knowledge, this is the first qualitative study to
assess NAFLD-awareness in a T2DM cohort and report
their knowledge regarding aetiology, pathophysiology,
treatment and disease progression of NAFLD, as well as
its relationship with T2DM. In this study, whilst half of
the participants recognized the concept of fatty liver,
awareness on NAFLD as a disease entity was only re-
ported by less than one-third of the participants, and
seemed to be associated with its diagnosis. Indeed, in
previous studies, NAFLD-aware patients were more
likely to be high-risk metabolic patients, to have a
history of liver disease or have undergone prior liver
function tests and have attended T2DM education
sessions [21, 23]. Higher than the percentage of
NAFLD aware patients in previous studies, this might
be the result of the high prevalence of NAFLD
amongst T2DM patients [11, 21, 23].
Nonetheless, knowledge on the aetiology, pathophysi-
ology and treatment of NAFLD was very scarce. Similar
to the results of previous studies, viral infection, alcohol
and medical drugs were mentioned as causes of fatty
liver, whilst those referring to the aetiology of NAFLD
unequivocally cited fat metabolism, referring to either
hypertriglyceridemia, hypercholesterolemia or the
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consumption of high-fat diets [60]. None of the partici-
pants referred to physical inactivity or heritability as
aetiological factors for NAFLD. The trend of undermin-
ing the role of physical activity in the aetiology of NAFL
D was also reflected when discussing therapeutic strat-
egies for this liver disease. These results also seem to
support findings of previous studies suggesting a lack of
perceived benefits of exercise practice amongst NAFLD
patients, perceptions that were thought to be responsible
for a lack of adherence to physical activity as preventive
or therapeutic behaviour [34, 60, 61]. These knowledge
gaps, together with a generalized tendency to undermine
the therapeutic status of dietary and physical activity re-
gimes, could be conductive of inadvertent non-
adherence.
Alongside the low rates of NAFLD awareness, the
poor understanding of liver physiology and fatty liver
pathophysiology might be precluding the formation of
beliefs and attitudes conductive of preventive behav-
iours. The most common conceptualization of hepatic
function devised the liver as a blood filter and con-
ceived a fatty liver as the state resulting from the re-
tention of fats following the depuration of fatty blood
attributed to hypertriglyceridemia, hypercholesterol-
emia or the consumption of fatty diets. Nonetheless,
our data portrays a generalized lack of knowledge on
the metabolic role of the liver. Moreover, being mis-
informed about the pathological consequences of stea-
tosis was prevalent.
Unlike NAFLD, awareness of the concept of cirrho-
sis as a disease entity was widely observed throughout
our sample. Almost ubiquitously recognized as a liver
pathology, excessive alcohol consumption was de-
scribed as the main aetiological factor for the disease
and invariably linked to cirrhosis awareness. Such
knowledge seemed to be learned vicariously, through
the life experiences of family members and friends.
Less common, but still prevalent was the notion that
cirrhosis is a life-threatening condition and that other
factors besides alcohol can also cause this end-stage
liver disease. Nonetheless, the nature of the non-
alcoholic aetiological factors reported was unknown in
most cases, only a minority recognizing NAFLD as a
risk factor for the development of cirrhosis.
Our findings underline a knowledge gap on the pro-
gression from non-alcoholic steatosis to end-stage
liver disease in this cohort. Moreover, the reported
low rates of participation in both preventive and sur-
veillance screenings, as well as the low level of con-
cern in the narratives regarding hepatic steatosis,
especially those portrayed by patients not engaging in
such programs, suggests a lack of perceived severity
of the health implications of a fatty liver diagnosis,
corroborating previous findings [24].
The detrimental potential of beliefs of low perceived
severity on the likelihood to take preventive action
could be further exacerbated by a lack of knowledge
on the increased susceptibility of T2DM patients in
developing NAFLD. Low NAFLD-awareness amongst
T2DM is particularly concerning due to the high
prevalence of NAFLD amongst this metabolic group
and the bidirectional synergistic interplay of these dis-
orders. On one hand, T2DM exacerbates the natural
course of NAFLD, promoting the development of
NASH, fibrosis and end-stage liver disease, including
cirrhosis and HCC. On the other hand, the presence
of NAFLD as comorbidity seems to be associated with
a worse metabolic profile, the need for higher insulin
doses and the severity of diabetic microvascular com-
plications in T2DM patients. Furthermore, those indi-
viduals with both T2DM and NAFLD are at a higher
risk of CVDs and report worse Health-Related Quality
of Life (HRQoL) [62–64].
The disassociation between the metabolic conditions
seemed apparent when discussing the pathophysiology
of these diseases. The patient’s narratives depicted
NAFLD as a fat-centric pathology driven by a disruption
of fat metabolic fluxes whilst T2DM was conceived as a
sugar-centric condition. The documented knowledge
gap on the concept of IR, the underlying aetiological
mechanism driving the pathophysiology of both NAFLD
and T2DM, could further explain this disassociation.
These results contrast those of previous quantitative
studies, which perhaps due to the guiding nature of their
multiple-choice questions, reported a moderate aware-
ness of the concept of IR and the relationship of NAFLD
with other metabolic disorders [21, 22].
Interestingly, our findings suggest that perceptions
around the relationship between NAFLD and T2DM
were constructed through personal and vicarious experi-
ences and depended upon the temporal sequence of
diagnosis. Patients who had a NAFLD diagnosis prior to
T2DM established no connection between the two meta-
bolic disorders. Conversely, a diagnosis of NAFLD as a
T2DM patient seemed to lead to the belief that this hep-
atic condition was a consequence of diabetes comparable
to T2DM macro- and micro-vesicular consequences
such as nephropathy, neuropathy or retinopathy [65].
Such a conclusion seems further supported by the fact
that the liver was mentioned as an organ affected by
T2DM regardless of NAFLD-awareness.
The low rates of NAFLD knowledge in this and other
studies suggest that a majority of T2DM patients, high-
risk metabolic patients and the general population would
benefit most from interventions that raise awareness on
the disease, thus facilitating the transition from an un-
awareness state to proactive stages of covert or even
overt behaviour [37, 66].
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Likely, stressing factual knowledge able to influence
the beliefs underlying behavioural intention might in-
duce unengaged NAFLD aware individuals to contem-
plate taking precautionary action against NAFLD
incidence or progression. Indeed, the NAFLD-aware par-
ticipants in our study displayed low levels of threat per-
ception regarding NAFLD. It would thus be expected,
that increasing knowledge in NAFLD progression to the
well-known life-threatening condition of cirrhosis would
increase the perceived level of severity attributed to
NAFLD as a disease entity.
Likewise, facilitating awareness on the concept of IR
and the increased risk of T2DM patients regarding the
incidence and severity of NAFLD could influence beliefs
of perceived susceptibility to the disease. As predicted by
the Health Belief Model (HBM), such increased aware-
ness, together with information highlighting the under-
lying effects of healthy diets and physical activity
regimes driving the benefits of endorsing such health be-
haviours should prompt the adoption of preventive and
therapeutic behaviours [35]. Increasing NAFLD aware-
ness amongst T2DM patients might increase participa-
tion in screening and surveillance programs for liver
disease, facilitating primary and secondary prevention,
but also boost the motivation to adhere to the lifestyle
intervention component of T2DM treatment.
Although this rationale remains to be tested through
intervention studies, research on the factors influencing
adherence reveals that especially for lifestyle interven-
tions, lack of information and self-management skills,
self-efficacy issues and lack of motivation are amongst
the major documented barriers for adherence [36, 67].
NAFLD perceived severity, disease knowledge and self-
efficacy seem to be correlated with better adherence to
dietary recommendations [60] whilst the level of concern
of dying due to HCC, self-confidence in HCC knowledge
and the patients’ degree of participation in decision-
making processes of their disease management have
been reported as predictors of utilization of HCC sur-
veillance services [68].
To strategically maximize its impact on factual
knowledge acquisition but also motivation and behav-
ioural skills, NAFLD health communication initiatives
should be designed to cater to the information needs
and skills of individuals and communities. For this
population, the construction of NAFLD knowledge
around the cultural model for liver physiology as a
blood filter as well as the shared explanatory models
and popular theories used to explain cirrhosis and
fatty liver could be of benefit [69–72].
Moreover, considering that the therapeutic plan for
NAFLD management is embedded within the treatment
approach for T2DM [73], diabetic patients with high
T2DM-awareness and self-management skills possess
privileged knowledge on NAFLD-relevant dietary and
exercise behaviours as compared to other non-diabetic
NAFLD patients. Yet, as reflected by this study, not all
patients possessed the same degree of T2DM self-
management knowledge [74–76]. Further research in
this direction might support the inclusion of NAFLD-
awareness material in T2DM self-management programs
to be conceived around the temporal dimension of
T2DM tacit knowledge acquisition, tailoring its content
according to their level of T2DM self-management
knowledge.
Strengths and limitations
This is to our knowledge the first qualitative study
addressing the topic of NAFLD awareness. Although
innovative, this study has several limitations. The single-
center study design and the small population cohort,
restricted to older individuals of Portuguese nationality
with low levels of formal education, limits the
generalizability, transferability and external validity of
our findings. Moreover, the adscription to confidentiality
protocols at the Portuguese Diabetes Association pre-
cluded member checking as a technique to further en-
sure the credibility and trustworthiness of the data.
Additionally, the lack of access to clinical data negated
correlation analysis between awareness and clinical
outcomes.
Our aim was not to infer the knowledge and percep-
tions at a population level, more representative of quan-
titative approaches already present in the literature, but
to grasp a better understanding of what NAFLD means
from first-hand experience and how this meaning is de-
rived, built and modelled by experience with T2DM.
The findings of this study can guide future research
informing the development of NAFLD-related messages
for public health interventions, especially those that seek
to extend awareness and participation of most vulner-
able groups in health promotion. In this study, over 56%
of the participants had not attained secondary education.
Low formal education is associated with low health liter-
acy and worse health outcomes. These populations are
the most burdened by chronic illnesses and the hardest
to engage in adherence and prevention programs [71,
77–80]. Moreover, not only do the participants of this
study represent a very small portion of total consulta-
tions at APDP, but they also differ considerably on their
degree of experience with the disease, as their T2DM
history ranges from 0 to 48 years. Illness experience is
related with beliefs of self-efficacy and self-management
knowledge, which in turn can shape the information
needs of these patients in regards to NAFLD [76]. Future
studies should address this issue.
By better addressing the needs of these communi-
ties, planning and implementation of public health
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interventions would be expected to increase the cap-
acity of these individuals to freely exert their health
citizenship. Future qualitative research exploring the
construct of NAFLD awareness with other popula-
tions and communities, exploring the relationship be-
tween NAFLD knowledge and health-related
behaviours, or querying for additional constructs such
as HCC, one of the main end-stage liver disease out-
comes of NAFLD would likely enhance the collective
capacity to respond to this public health threat.
Conclusions
NAFLD represents one of the most pressing public
health threats today and awareness of this disease entity
was low amongst the participants in this study, which as
T2DM patients are at a higher risk of suffering from this
chronic disease. Although the construct of cirrhosis was
familiar to the majority of respondents, knowledge on
the relationship between NAFLD, T2DM and end-stage
liver disease was low. Unmet information needs under
the theoretical construct of NAFLD-awareness hinder
not only NAFLD diagnosis and management at an
organizational level but might also be precluding meta-
bolic patients from actively participating in the decisions
concerning their health, including adherence to treat-
ment and surveillance. The information gathered in
these qualitative research studies can be used as input
for the development of tailored health communication
initiatives and self-management programs ultimately fa-
cilitating adherence to treatment as well as primary and
secondary NAFLD prevention.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12889-020-09249-5.
Additional file 1 Semi-structured interview guide
Additional file 2. SRQR Checklist
Abbreviations
APDP: Portuguese Diabetes Association; CVDs: Cardiovascular Diseases;
HBM: Health Belief Model; HCC: Hepatocellular Carcinoma; HRQoL: Health-
Related Quality of Life; IR: Insulin Resistance; MetS: Metabolic Syndrome;
NAFLD: Non-Alcoholic Fatty Liver Disease; PAPM: Precaution Adoption
Prevention Model; T2DM: Type 2 Diabetes Mellitus
Acknowledgements
This research was conducted at the Portuguese Diabetes Association (APDP).
The authors are grateful to all the participants and APDP staff members for
making this study possible. The authors also thank Alexandra Carvalho and
Francisco Freitas (CES, Center for Social Studies at the University of Coimbra)
for the transcription verbatim of the voice recordings and MAXQDA2018
consulting services, respectively.
Authors’ contributions
MAP contributed to the conception and design, data acquisition, data
analysis and manuscript writing. MMR contributed to the conception and
design of the study, data analysis and edition of the paper. RTR and DO
contributed to the conception and implementation of the study. SA, MPM
and JRS contributed to the conception and design of the study and edition
of the paper. AMA contributed to the conception and design of the study,
data acquisition and edition of the paper. All authors have read and
approved the manuscript.
Funding
This study received support from the FOIE GRAS project, funded by the
European Union’s Horizon 2020, Research and Innovation programme under
the Marie Skłodowska-Curie Grant Agreement No. 722619 and the European
Regional Development Fund (ERDF), through the COMPETE 2020 –
Operational Programme for Competitiveness and Internationalisation and
Portuguese national funds via FCT – Fundação para a Ciência e a Tecnologia,
under the project UID/NEU/04539/2019. The funding bodies did not partake
in the study design, the collection, analysis or interpretation of the data. Nor
in manuscript drafting processes.
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the Ethics Committee for Health of the
Portuguese Diabetes Association (APDP, N°231/2018). Written informed
consent was obtained from all participants in the study.
Consent for publication
Not applicable.
Competing interests
None of the authors have potential conflicts of interest to be disclosed.
Author details
1CNC-Center for Neuroscience and Cell Biology, CIBB, Rua Larga, University of
Coimbra, Rua Larga, 3000-504 Coimbra, Portugal. 2University of Coimbra,
IIIUC-Institute for Interdisciplinary Research, 3030-789 Coimbra, Portugal.
3Centro Hospitalar e Universitário de Coimbra, Reproductive Medicine Unit,
Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal. 4Center for Research in
Neuropsychology and Cognitive Behavioral Intervention, Faculty of
Psychology and Educational Sciences, University of Coimbra, Rua do Colégio
Novo, 3000-115 Coimbra, Portugal. 5CES-Centre for Social Studies, University
of Coimbra, 3000-104 Coimbra, Portugal. 6APDP-Portuguese Diabetic
Association, 1250-189 Lisbon, Portugal. 7CEDOC-Centro de Estudos de
Doenças Crónicas, NOVA Medical School/Faculdade de Ciências Médicas,
1150-082 Lisbon, Portugal. 8Department of Medical Sciences, University of
Aveiro, 3810-193 Aveiro, Portugal. 9Department of Life Sciences, Calçada
Martim de Freitas, University of Coimbra, 3000-456 Coimbra, Portugal.
Received: 5 February 2020 Accepted: 12 July 2020
References
1. Younossi ZM. Non-alcoholic fatty liver disease – a global public health
perspective. J Hepatol. 2019;70(3):531–44. https://doi.org/10.1016/j.jhep.
2018.10.033.
2. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in
the world. J Hepatol. 2019;70(1):151–71. https://doi.org/10.1016/j.jhep.
2018.09.014.
3. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic
of nonalcoholic fatty liver disease demonstrates an exponential increase in
burden of disease. Hepatology. 2018;67(1):123–33.
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo
Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;
55(7):434–8.
5. Byrne CD, Targher G. Review NAFLD : a multisystem disease. J Hepatol.
2015;62(1):S47–64. https://doi.org/10.1016/j.jhep.2014.12.012.
6. Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology.
1998;114(4):842–5. https://doi.org/10.1016/S0016-5085(98)70599-2.
7. Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease :
pathogenesis and disease spectrum. Annu Rev Pathol. 2016;11:451–96.
Alemany-Pagès et al. BMC Public Health         (2020) 20:1142 Page 12 of 14
8. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms
of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):
908–22.
9. Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al.
Nonalcoholic fatty liver disease. Nat Rev Dis Prim. 2015;1:1–22.
10. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a
consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;
2(11):901–10.
11. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global
epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment
of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
12. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson
PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty
liver disease. Gastroenterology. 2018;155(6):1828–1837.e2.
13. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH
to HCC: current concepts and future challenges. Nat Rev Gastroenterol
Hepatol. 2019;16(7):411–28.
14. Pimpin L, Cortez-pinto H, Negro F, Corbould E, Lazarus V, Webber L, et al.
Burden of liver disease in Europe : epidemiology and analysis of risk factors
to identify prevention policies. J Hepatol. 2018. https://doi.org/10.1016/j.
jhep.2018.05.011.
15. Cai J, Zhang X, Li H. Progress and challenges in the prevention and control
of nonalcoholic fatty liver disease. Med Res Rev. 2018;39:1–21.
16. Bellentani S, Grave RD, Suppini A. Behavior therapy for nonalcoholic fatty
liver disease: the need for a multidisciplinary approach. Hepatology. 2008;
47(2):746–54.
17. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD
in clinical practice to answers from guidelines. J Hepatol. 2013;59(4):859–71.
18. Wieland AC, Quallick M. Identifying practice gaps to optimize medical care
for patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58(10):
2809–16.
19. Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, et al.
Underappreciation of non-alcoholic fatty liver disease by primary care
clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J.
2018;48(2):144–51.
20. Briceno SP, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic
steatohepatitis and associated practice patterns of primary care physicians
and specialists. BMC Res Notes. 2016;9:1–12.
21. Leung CM, Lai LSW, Wong WH, Chan KH, Luk YW, Lai JY, et al. Non-alcoholic
fatty liver disease: an expanding problem with low levels of awareness in
Hong Kong. J Gastroenterol Hepatol. 2009;24(11):1786–90.
22. Ghevariya V, Sandar N, Patel K, Ghevariya N, Shah R, Aron J. Knowing what ’
s out there : awareness of non-alcoholic fatty liver disease. Front Med. 2014;
1(March):1–5.
23. Wieland AC, Mettler P, Mcdermott MT, Crane LA, Cicutto LC, Bambha KM.
Low Awareness of Nonalcoholic Fatty Liver Disease Among Patients at High
Metabolic Risk. J Clin Gastroenterol. 2015;49(1):e6–e10.
24. Mlynarsky L, Schlesinger D, Lotan R, Webb M, Halpern Z, Santo E, et al. Non-
alcoholic fatty liver disease is not associated with a lower health perception.
World J Gastroenterol. 2016;22(17):4362–72.
25. Kastorini C-M, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA,
Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome
and its components: a meta-analysis of 50 studies and 534,906 individuals. J
Am Coll Cardiol. 2011;57(11):1299–313 http://www.sciencedirect.com/
science/article/pii/S0735109710050679.
26. Barrera F, George J. The role of diet and nutritional intervention for the
management of patients with NAFLD. Clin Liver Dis. 2014;18(1):91–112.
https://doi.org/10.1016/j.cld.2013.09.009.
27. Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D,
et al. Adherence to the Mediterranean diet is associated with the severity of
non-alcoholic fatty liver disease. Clin Nutr. 2013;33:6–11.
28. Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V, et al. EASL-
EASD-EASO clinical practice guidelines for the management of non-
alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. https://doi.org/
10.1016/j.jhep.2015.11.004.
29. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet,
physical activity and exercise. J Hepatol. 2017;67(4):829–46.
30. Lazarus JV, Ekstedt M, Tacke F, Cortez H, Anstee QM, Pericàs JM, et al. A
cross-sectional study of the public health response to non-alcoholic fatty
liver disease in Europe non-alcoholic fatty liver disease in Europe. J Hepatol.
2019. https://doi.org/10.1016/j.jhep.2019.08.027.
31. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-
Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle
modification significantly reduces features of nonalcoholic steatohepatitis.
Gastroenterology. 2015;149(2):367–378.e5. https://doi.org/10.1053/j.gastro.
2015.04.005.
32. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, et al.
Community-based lifestyle modification programme for non-alcoholic fatty
liver disease : a randomized controlled trial. J Hepatol. 2013;59(3):536–42.
https://doi.org/10.1016/j.jhep.2013.04.013.
33. Arab A, Askari G, Golshiri P, Feizi A, Hekmatnia A, Iraj B, et al. The effect of a
lifestyle modification education on adiposity measures in overweight and
obese nonalcoholic fatty liver disease patients. Int J Prev Med. 2017;8:10.
34. Centis E, Moscatiello S, Bugianesi E, Bellentani S, Fracanzani AL, Calugi S,
et al. Stage of change and motivation to healthier lifestyle in non-alcoholic
fatty liver disease. J Hepatol. 2013;58(4):771–7. https://doi.org/10.1016/j.jhep.
2012.11.031.
35. Janz K, Becker MH. The health belief model : a decade later. Health Educ Q.
1984;11:1–47.
36. Fisher WA, Fisher JD, Harman J. The information-motivation-behavioraI skills
model: a general social psychological approach to understanding and
promoting health behavior. In: Social psychological foundations of health
and illness. Fisher, William A.: U Western Ontario, Dept of Psychology,
London, ON, Canada, N6A 5C2, fisher@uwo.ca: Blackwell Publishing; 2003. p.
82–106. (Blackwell series in health psychology and behavioral medicine.).
37. Glanz K, Rimer BK, Viswanath K. Health behavior and health education :
theory, research, and practice. San Francisco: Jossey-Bass; 2008.
38. Bandura A. Self-efficacy: toward a unifying theory of behavioral change.
Psychol Rev. 1977;84:191–215 US: American Psychological Association.
39. The NASH Education Program [Internet]. 2018 [cited 2018 Jun 27]. Available
from: https://www.the-nash-education-program.com/.
40. British Liver Trust [Internet]. [cited 2017 Aug 15]. Available from: https://
www.britishlivertrust.org.uk/.
41. Trovato FM, Catalano D, Martines GF, Pace P, Trovato GM. Mediterranean
diet and non-alcoholic fatty liver disease the need of extended and
comprehensive interventions. Clin Nutr. 2015;34(1):86–8. https://doi.org/10.
1016/j.clnu.2014.01.018.
42. Hallsworth K, Avery L, Trenell MI. Targeting lifestyle behavior change in
adults with NAFLD during a 20-min consultation : summary of the dietary
and exercise literature. Curr Gastroentrol Rep. 2016;18:1–7.
43. Nutbeam D. The evolving concept of health literacy. Soc Sci Med. 2008;
67(12):2072–8. https://doi.org/10.1016/j.socscimed.2008.09.050.
44. Nutbeam D. Health literacy as a public health goal: a challenge for
contemporary health education and communication strategies into the 21st
century. Health Promot Int. 2000;15(3):259–67. https://doi.org/10.1093/
heapro/15.3.259.
45. Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver
disease and cardiovascular risk: pathophysiological mechanisms and
implications. J Hepatol. 2016;65(2):425–43.
46. Al-Busaidi ZQ. Qualitative research and its uses in health care. Sultan
Qaboos Univ Med J. 2008;8(1):11–9.
47. Lambert VA, Lambert CE. Editorial : qualitative descriptive research : an
acceptable design. Pac Rim Int J Nurs Res. 2012;16(4):255–6.
48. Associação Protectora dos Diabéticos de Portugal A. Portuguese Diabetes
Association [Internet]. Available from: apdp.pt.
49. Laranjo L, Neves AL, Costa A, Ribeiro RT, Couto L, Sa AB. Facilitators, barriers
and expectations in the self-management of type 2 diabetes--a qualitative
study from Portugal. Eur J Gen Pract. 2015;21(2):103–10.
50. Ribeiro RT, Boavida JM. Comparison of healthcare costs between an
implemented integrated diabetes care unit and the traditional national
health system comparison of healthcare costs between an implemented
integrated diabetes care unit and the traditional national health system.
2016;(December).
51. Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K.
Purposeful sampling for qualitative data collection and analysis in
mixed method implementation research. Admin Pol Ment Health. 2015;
42(5):533–44.
52. Sandelowski M. Sample size in qualitative research. Res Nurs Health. 1995;
18(2):179–83.
53. Krippendorff KH. Content analysis: an introduction to its methodology.
54. VERBI Software. MAXQDA 2018 [computer software]. Berlin: VERBI Software;
2017. p. 2017.
Alemany-Pagès et al. BMC Public Health         (2020) 20:1142 Page 13 of 14
55. Korstjens I, Moser A. Series: practical guidance to qualitative research. Part 4:
trustworthiness and publishing. Eur J Gen Pract. 2018;24(1):120–4. https://
doi.org/10.1080/13814788.2017.1375092.
56. Sim J, Sharp K. A critical appraisal of the role of triangulation in nursing
research. Int J Nurs Stud. 1998;35(1–2):23–31.
57. Lincoln SY, Guba EG. Naturalistic inquiry. Beverly Hills: Sage Publications, Inc.;
1985.
58. Mchugh ML. Lessons in biostatistics Interrater reliability : the kappa statistic.
Boichem Med. 2012;22:276–82.
59. Global report on diabetes. World heal organ. 2016;.
60. Zelber-sagi S, Bord S, Dror-lavi G, Smith ML, Towne SD Jr, Buch A, et al. Role
of illness perception and self-efficacy in lifestyle modification among non-
alcoholic fatty liver disease patients. World J Gastroenterol. 2017;23(10):
1881–90.
61. Frith J, Day CP, Robinson L, Elliott C, Jones DEJ, Newton JL. Potential
strategies to improve uptake of exercise interventions in non-alcoholic fatty
liver disease. J Hepatol. 2010;52(1):112–6. https://doi.org/10.1016/j.jhep.2009.
10.010.
62. Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients
with type 2 diabetes : a call to action. Diabetes Care. 2017;40(March):419–30.
63. Younossi ZM. Practice management : the road ahead patient-reported
outcomes for patients with chronic liver disease. Clin Gastroenterol Hepatol.
2018. https://doi.org/10.1016/j.cgh.2017.12.028.
64. Kennedy-Martin T, Bae JP, Paczkowski R, Freeman E. Health-related quality of
life burden of nonalcoholic steatohepatitis : a robust pragmatic literature
review. J Patient Rep Outcomes. 2018;2:1–14.
65. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al.
Association of glycaemia with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 35): prospective observational
study. BMJ. 2000;321(7258):405–12.
66. Weinstein ND, Blalock SJ, Sandman PM, Weinstein ND. The precaution
adoption process model the precaution adoption process model; 2008.
67. World Health Organization. Adherence to long-term therapies. Geneva:
World Health Organization; 2003. p. 2003.
68. Singal AG, Volk ML, Rakoski MO, Fu S, Su GL, Mccurdy H, et al. Patient
involvement in healthcare is associated with higher rates of surveillance for
hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(8):727–32.
69. Young A. When rational men fall sick: an inquiry into some assumptions
made by medical anthropologists. Cult Med Psychiatry. 1981;5(4):317–35.
70. D’Andrade RG, Strauss C. Human motives and cultural models [internet].
Publications of the Society for Psychological Anthropology. Cambridge:
Cambridge University Press; 1992. Available from: https://www.cambridge.
org/core/books/human-motives-and-cultural-models/A75A5E175145304
BB07B798698D6495B.
71. Groleau D. Embodying ‘ health citizenship ’ in health knowledge to fi ght
health inequalities. Rev Bras Enferm. 2011;64(5):811–6.
72. Kleinman A. Patients and healers in the context of culture : an exploration
of the borderland between anthropology, medicine, and psychiatry.
Berkeley: University of California Press; 1980.
73. Sumida Y, Yoneda M. Current and future pharmacological therapies for
NAFLD / NASH. J Gastroenterol. 2018;53(3):362–76. https://doi.org/10.1007/
s00535-017-1415-1.
74. Coates VE, Boore JRP. Self-management of chronic illness: implications for
nursing. Int J Nurs Stud. 1995;32(6):628–40 Available from: http://www.
sciencedirect.com/science/article/pii/0020748995000435.
75. Bury M. The sociology of chronic illness : a review of research and
prospects. Sociol Health Illn. 1991;13(4):451–68.
76. Price MJ. An experiential model of learning diabetes self-management. Qual
Health Res. 1993;3(1):29–54. https://doi.org/10.1177/104973239300300103.
77. Dahal PK, Hosseinzadeh H. Association of health literacy and diabetes self-
management : a systematic review; 2018.
78. Caruso R, Magon A, Baroni I, Dellafiore F. Health literacy in type 2 diabetes
patients : a systematic review of systematic reviews. Acta Diabetol. 2017;
55(1):1–12.
79. Schillinger D, Grumbach K, Piette J, Wang F, Osmond D, Daher C, et al.
Association of health literacy with diabetes outcomes. JAMA. 2002;288(4):
475–82.
80. Powell CK, Hill EG, Clancy DE. The relationship between health literacy and
diabetes knowledge and readiness to take health actions. Diabetes Educ.
2007;33(1):144–51.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Alemany-Pagès et al. BMC Public Health         (2020) 20:1142 Page 14 of 14
